Health Care Services

Guardant Health

Manulife Singapore to Launch Shield™ Multi-Cancer Test with Guardant Health in May 2026

Guardant Health Reports Significant Losses in Q4 2025 Earnings

Guardant Health released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 301.67 M (forecast USD 279.06 M), actual EPS USD -0.8537 (forecast USD -0.806)

Guardant Health reports 48% revenue growth to $301.7 million in Q1

Guardant Health's Guardant360® CDx Approved by FDA as Companion Diagnostic for Late-Stage Breast Cancer

Pictet Asset Management Reduces Stake in Guardant Health

Jennison Associates LLC reduced stake in Guardant Health

Guardant Health to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 279M, EPS USD -0.806

Guardant Health's Chief People Officer Sells Company Shares

Guardant Health to Present 28 Abstracts at AACR Annual Meeting

Guardant Health Partners with Manulife Financial to Launch Shield Multi-Cancer Blood Test in Asia

Patrick Dempsey Partners with Guardant Health to Promote Colorectal Cancer Screening

Assetmark Inc. Significantly Increases Holdings in Guardant Health

Guardant Health released FY2025 Q4 earnings on February 19 After-Market (EST), actual revenue USD 0 (forecast USD 272.28 M), actual EPS USD 0 (forecast USD -0.773)

Guardant Health released FY2025 annual earnings on February 19 After-Market (EST), actual revenue USD 982.02 M (forecast USD 972.5 M), actual EPS USD -3.3202 (forecast USD -3.0936)

Guardant Health to release FY2025 Q4 earnings on February 19 After-Market EST, forecast revenue USD 271.77 M, EPS USD -0.7722

Guardant Health Approved by FDA and Partners with Merck, Stock Performance Strong

Guardant Health Inc. Collaborates with Merck to Develop Cancer Therapies

Guardant Health Announces Preliminary Unaudited Results for Full Year 2025 and Q4

Guardant Health's Chief Human Resources Officer Sells 10,031 Shares of Common Stock

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

InMed Pharmaceuticals

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

NextNRG

Generation Income Properties

MetaVia

CN Energy

Co-Diagnostics

IDNA

Guardant Health, Inc. announced the approval of restricted stock units (RSUs) for 267 new non-executive employees, totaling 143,898 shares, under the 2023 Employment Inducement Incentive Award Plan. The RSUs, granted as inducements for employment, will vest annually over three years. This action complies with Nasdaq Listing Rule 5635(c)(4).

StockTitan

VanEck Biotech ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

iShares Genomics Immunology and Healthcare ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GH Stock News

00945

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

MANULIFE-S

Manulife Financial

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

China Merchants CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

Manulife Singapore to offer multi-cancer blood test starting May

World Investment Advisors acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) by purchasing 16,290 shares valued at approximately $1.66 million in Q4. Other investors, including AQR Capital Management and Sei Investments, also increased their holdings. Guardant Health's stock opened at $94.92, with a market cap of $12.59 billion. The company reported a quarterly revenue of $281.27 million, up 39.4% year-over-year, but missed EPS estimates. Analysts have mixed ratings, with a consensus price target of $129.42.

Market Beat

iShares US Healthcare Providers

Health Care Select Sector SPDR

iShares US Medical Devices

SEI Investments

Raymond James Financial

Barclays

UBS Group AG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

World Investment Advisors Purchases New Position in Guardant Health, Inc. $GH

Wells Fargo analyst Brandon Couillard has maintained a Buy rating on Guardant Health (GH) with a price target of $125.00. Couillard, a 5-star analyst, has an average return of 15.6% and a success rate of 58.51%. Guardant Health also received a Buy rating from Guggenheim’s Subbu Nambi, while Evercore ISI maintained a Hold rating on May 8.

Tip Ranks

Wells Fargo

Bio-Rad Lab

Myriad Genetic

Evercore

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Bio-Rad Lab-B

Guardant Health (GH) Gets a Buy from Wells Fargo

BTIG analyst Mark Massaro has reaffirmed a Buy rating on Guardant Health (GH) with a price target of $145.00, while the shares closed at $95.70. On the same day, TD Cowen's Daniel Brennan also issued a Buy rating, but Evercore ISI maintained a Hold rating. Massaro has an average return of -4.7% and a 31.91% success rate on his stock recommendations.

Cerus

Sophia Genetics SA

Neogenomics

BTIG Reaffirms Their Buy Rating on Guardant Health (GH)

Guardant Health (GH) reported FY 2025 Q4 revenue of $281.3 million, with a basic EPS loss of $1.00 and a net income loss of $128.5 million. Despite a revenue increase from $201.8 million in Q4 FY 2024, the company continues to face significant losses, totaling $416.3 million on a trailing twelve month basis. Analysts forecast a 20.9% annual revenue growth, but profitability remains elusive. The stock trades at a premium P/S of 12.5x, raising concerns about valuation sensitivity to growth expectations. Investors are divided on the company's long-term growth potential versus its ongoing cash burn and balance sheet risks.

Simplywall

Guardant Health (GH) Earnings Spotlight Revenue Growth Versus Persistent Losses Challenges Premium Valuation Narratives

JPMorgan Chase & Co. has raised its price target for Guardant Health (NASDAQ:GH) from $130 to $135, maintaining an "overweight" rating. This suggests a potential upside of 47.11% from the stock's previous close. Other brokerages have also increased their price targets, with a consensus rating of "Moderate Buy" and a target price of $129.16. Guardant Health's stock traded down 0.5% to $91.77, with a market cap of $12.17 billion. The company reported a revenue increase of 39.4% year-over-year, despite missing EPS estimates.

JPMorgan Chase

Stifel Financial

Citigroup

T. Rowe Price

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Guardant Health (NASDAQ:GH) Stock

Earnings Watch

Guardant Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 301.67 M

Guardant Health (NASDAQ:GH) reported quarterly earnings of ($0.45) EPS, beating estimates of ($0.47) by $0.02. Revenue reached $301.67 million, exceeding the $279.15 million forecast and up 48.3% year-over-year. The company raised its 2026 revenue guidance to $1.30B–$1.32B, indicating strong growth. Despite a 34% increase in operating expenses and a free cash flow burn of $71M, Guardant maintains $1.2B in cash. The stock traded at $92.26, with a market cap of $12.23 billion. Insider transactions showed recent sales by directors, and institutional investors increased their stakes.

Merck

Nuvalent

Guardant Health (NASDAQ:GH) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Guardant Health(GH.US)